Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Investments (2018 - 2025)

Ascendis Pharma A's Long-Term Investments history spans 2 years, with the latest figure at $17.2 million for Q4 2019.

  • For Q4 2019, Long-Term Investments fell 11.79% year-over-year to $17.2 million; the TTM value through Dec 2019 reached $17.2 million, down 11.79%, while the annual FY2019 figure was $17.4 million, 10.75% down from the prior year.
  • Long-Term Investments for Q4 2019 was $17.2 million at Ascendis Pharma A, down from $19.5 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $19.5 million in Q4 2018 and bottomed at $17.2 million in Q4 2019.